SSR3

SSR3 (TRAPγ) is a subunit of the ER membrane translocon-associated protein (TRAP) complex and is required for protein translocation across the ER membrane and for fidelity of N-linked glycosylation (PMID:33523898, PMID:32332102). SSR3 is essential for the structural integrity of the TRAP complex: loss of SSR3 destabilizes the entire complex with concomitant reduction of SSR1 and SSR4, and re-expression of wild-type SSR3 restores all subunit levels and corrects glycosylation defects (PMID:30945312). Its extramembranous domain is primarily cytosolic, distinguishing it topologically from other TRAP subunits (PMID:34857543, PMID:33811688). SSR3 plays a rate-limiting role in cotranslational and posttranslational translocation of preproinsulin: its diminution inhibits preproinsulin translocation without affecting SSR1 levels, acute high glucose upregulates SSR3 protein (independent of mRNA) to drive proinsulin biosynthesis, and SSR3 overexpression raises proinsulin levels even without glucose (PMID:34857543). SSR3 protein abundance is itself regulated post-translationally in an ER-stress- and UBE2J1-dependent manner, coupling N-glycosylation proficiency to ER-associated degradation (PMID:33523898). Beyond the secretory pathway, SSR3 is required for placental vascular development in mice (PMID:21246656) and modulates susceptibility to paclitaxel through regulation of IRE1α phosphorylation (PMID:35552677). Homozygous loss-of-function variants in SSR3 cause a congenital disorder of glycosylation (PMID:30945312, PMID:32332102).

1. 2011 High

   Establishing whether SSR3 has an organism-level requirement, knockout defined it as essential for development, particularly placental vascular formation.

   Evidence Genetic knockout mouse with placental histology, proliferation and apoptosis assays

   PMID:21246656

   Open questions at the time

   • Does not connect the developmental phenotype to a specific molecular defect in translocation or glycosylation
   • Mechanism of vascular endothelial proliferation failure unresolved
2. 2019 High

   To test whether SSR3 loss causes human disease and how, a patient frameshift variant was shown to destabilize the whole TRAP complex and impair glycosylation, with rescue confirming causality.

   Evidence Exome sequencing, western blot of TRAP subunits in patient fibroblasts, rescue by wild-type SSR3, glycosylation assay on GP130/ICAM1

   PMID:30945312

   Open questions at the time

   • Does not define which clients depend on SSR3 for translocation versus glycosylation
   • Structural basis of complex destabilization not resolved
3. 2020 Medium

   A second patient variant (start codon) confirmed SSR3 is required for TRAP integrity, ER translocation, and N-glycosylation site occupancy.

   Evidence Patient-cell biochemistry: translocation assay, glycosylation site occupancy, brush-border transport assay

   PMID:32332102

   Open questions at the time

   • Single patient, single lab, no rescue experiment
   • Tissue-specific consequences not generalized
4. 2021 High

   To define SSR3 within ER stress biology, it was shown to maintain N-glycosylation fidelity during ER stress and to be itself regulated post-translationally via UBE2J1, coupling glycosylation status to ERAD.

   Evidence Fluorescence N-glycosylation reporter, CRISPR/siRNA KO of SSR3/SSR4, BiP silencing rescue, UBE2J1-dependent protein level assay

   PMID:33523898

   Open questions at the time

   • Direct biochemical interaction between SSR3 and UBE2J1 not shown
   • Which glycoproteins are most sensitive to SSR3 loss not enumerated
5. 2021 High

   Perturbing other TRAP subunits clarified the interdependence of the complex, showing SSR2/SSR4 loss reduces SSR3 levels and proinsulin biosynthesis, and positioned SSR3 topology as primarily cytosolic.

   Evidence siRNA KD of SSR2/SSR4 in β-cells, amino acid pulse labeling, western blot, subunit re-expression rescue

   PMID:33811688

   Open questions at the time

   • Stoichiometry and direct contacts of SSR3 within the complex not mapped
   • Does not isolate SSR3-specific function from complex-wide effects
6. 2022 High

   Direct interrogation of SSR3 function in β-cells defined a rate-limiting, glucose-responsive role in preproinsulin translocation.

   Evidence siRNA KD and overexpression of SSR3 in β-cell lines and human islets, glucose-stimulation assays, western blot for SSR1 and proinsulin

   PMID:34857543

   Open questions at the time

   • Mechanism of post-transcriptional SSR3 upregulation by glucose not defined
   • Whether SSR3 acts as a dedicated preproinsulin translocation factor or generally on signal-peptide-bearing clients unresolved
7. 2022 Medium

   A CRISPR screen linked SSR3 to chemotherapy response, showing it modulates paclitaxel susceptibility via IRE1α phosphorylation.

   Evidence Genome-wide CRISPR KO screen in glioma, KO/overexpression in breast and glioma cells, intracranial xenografts, IRE1α phosphorylation assay

   PMID:35552677

   Open questions at the time

   • Mechanistic link to IRE1α phosphorylation described with limited detail
   • Whether the effect depends on TRAP-mediated translocation versus a separable activity not resolved

• How SSR3's cytosolic domain mechanistically promotes translocation of specific clients, and the structural basis of its role in TRAP assembly, remain open.
• No structural model of SSR3 within the assembled translocon
• Client selectivity rules for SSR3-dependent translocation unknown
• Direct biochemical partners of the cytosolic domain not identified